Welcome to our new Chief Fellow, Dr. Alexandra Rojek!! We know she will do great things this year and are thrilled for her to be in this leadership role! Congratulations, Dr. Rojek! University of Chicago Hem/Onc Fellows

Out now in ASCO Daily News... Belantamab Mafodotin Triplet Regimens: A “Plight” for Sore Eyes or La “Bela” Vita? dailynews.ascopubs.org/do/belantamab-…

The DREAMM-7 & DREAMM-8 studies established the effectiveness of belamaf-based triplet regimens in pts w/ R/R MM who had received ≥1 prior line of therapy. Ben Derman examines the potential of belamaf + Vd and belamaf + Pd for #ASCODailyNews: brnw.ch/21wLgIy #mmsm

What is it like to attend a predatory conference? nature.com/articles/d4158…

It’s out! After 14+ long years of enrollment, analysis and follow up the CoMMpass trial is published in full format nam11.safelinks.protection.outlook.com/?url=https%3A%…. Thanks to J Keats, all the investigators, Multiple Myeloma RF and to the patients who were part of this landmark study.

TL;DR - Earlier this week, FDA denied (read: likely delayed) approval of linvoseltamab due to manufacturing facility concerns; seems like it was expected. No clear timeline. biospace.com/fda/fda-denies…

Raj Chakraborty 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy ashpublications.org/blood/article-…

Mass spectrometry (MS)–based assessment of M protein in peripheral blood during maintenance Rx in MM. MS complements BM MRD #mmsm #bmtsm Ben Derman Blood Journal ashpublications.org/blood/article/…

How do you approach patients with AL amyloidosis with high plasmacytosis in the bone marrow (ex. 35%) but no other evidence of myeloma?

One more clinical conundrum. How do you approach patients with biopsy-proven PGNMID and ESRD who are considering kidney transplant? (No detectable disease in marrow or blood; urine protein cannot adequately be monitored)

Ben Derman Put them on s2213! The SWOG trial evaluating the role of transplant. We don't know the optimal endpoint in AL... CR sounds great but data is clear that mrd negativity in the BM by NGF or NGS and in the peripheral blood by mass spec leads to improved outcomes across the board.